Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876644 | 0.99 | SOAT1 (0.51) | SOAT1KMT2ADRD4DRD2CA12 | |
| Hydrochloric Acid SCHEMBL4880951 | 0.98 | SOAT1 (0.51) | SOAT1KMT2ADRD4DRD2CA12 | |
| SCHEMBL4876387 | 0.89 | SOAT1 (0.47) | SOAT1DRD4DRD2 | |
| SCHEMBL4881137 | 0.88 | CA12 (0.49) | SOAT1KMT2ADRD2CA12CA1 | |
| SCHEMBL4878061 | 0.86 | SOAT1 (0.58) | SOAT1KMT2ADRD4DRD2HTR1A | |
| SCHEMBL4880541 | 0.85 | SOAT1 (0.48) | SOAT1KMT2ADRD4CA12CA1 | |
| SCHEMBL5476169 | 0.85 | SOAT1 (0.55) | SOAT1KMT2ADRD4DRD2HTR1A | |
| SCHEMBL4876527 | 0.84 | SOAT1 (0.57) | SOAT1DRD4DRD2 | |
| SCHEMBL4881690 | 0.84 | HTR1A (0.40) | SOAT1KMT2ADRD4DRD2HTR1A | |
| SCHEMBL4873768 | 0.84 | SOAT1 (0.55) | SOAT1KMT2ADRD4DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | SOAT1 502/4885KMT2A 1132/4885DRD4 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.